| Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA K Karikó, M Buckstein, H Ni, D Weissman Immunity 23 (2), 165-175, 2005 | 2563 | 2005 |
| mRNA-based therapeutics—developing a new class of drugs U Sahin, K Karikó, Ö Türeci Nature reviews Drug discovery 13 (10), 759-780, 2014 | 2339 | 2014 |
| COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses U Sahin, A Muik, E Derhovanessian, I Vogler, LM Kranz, M Vormehr, ... Nature 586 (7830), 594-599, 2020 | 1995 | 2020 |
| Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability K Karikó, H Muramatsu, FA Welsh, J Ludwig, H Kato, S Akira, ... Molecular therapy 16 (11), 1833-1840, 2008 | 1959 | 2008 |
| mRNA is an endogenous ligand for Toll-like receptor 3 K Karikó, H Ni, J Capodici, M Lamphier, D Weissman Journal of Biological Chemistry 279 (13), 12542-12550, 2004 | 1365 | 2004 |
| Sequence-and target-independent angiogenesis suppression by siRNA via TLR3 ME Kleinman, K Yamada, A Takeda, V Chandrasekaran, M Nozaki, ... Nature 452 (7187), 591-597, 2008 | 1115 | 2008 |
| Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA K Karikó, H Muramatsu, J Ludwig, D Weissman Nucleic acids research 39 (21), e142-e142, 2011 | 1005 | 2011 |
| Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination N Pardi, MJ Hogan, RS Pelc, H Muramatsu, H Andersen, CR DeMaso, ... Nature 543 (7644), 248-251, 2017 | 953 | 2017 |
| Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes N Pardi, S Tuyishime, H Muramatsu, K Kariko, BL Mui, YK Tam, ... Journal of Controlled Release 217, 345-351, 2015 | 933 | 2015 |
| DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration H Kaneko, S Dridi, V Tarallo, BD Gelfand, BJ Fowler, WG Cho, ... Nature 471 (7338), 325-330, 2011 | 718 | 2011 |
| BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans U Sahin, A Muik, I Vogler, E Derhovanessian, LM Kranz, M Vormehr, ... Nature 595 (7868), 572-577, 2021 | 712 | 2021 |
| Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation BR Anderson, H Muramatsu, SR Nallagatla, PC Bevilacqua, LH Sansing, ... Nucleic acids research 38 (17), 5884-5892, 2010 | 704 | 2010 |
| Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3 K Karikó, P Bhuyan, J Capodici, D Weissman The Journal of Immunology 172 (11), 6545-6549, 2004 | 578 | 2004 |
| Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses N Pardi, MJ Hogan, MS Naradikian, K Parkhouse, DW Cain, L Jones, ... Journal of Experimental Medicine 215 (6), 1571-1588, 2018 | 503 | 2018 |
| Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses MG Alameh, I Tombácz, E Bettini, K Lederer, S Ndeupen, C Sittplangkoon, ... Immunity 54 (12), 2877-2892. e7, 2021 | 454 | 2021 |
| Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference J Capodici, K Karikó, D Weissman The Journal of Immunology 169 (9), 5196-5201, 2002 | 449 | 2002 |
| Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin K Karikó, H Muramatsu, JM Keller, D Weissman Molecular Therapy 20 (5), 948-953, 2012 | 407 | 2012 |
| A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA M Baiersdörfer, G Boros, H Muramatsu, A Mahiny, I Vlatkovic, U Sahin, ... Molecular Therapy-Nucleic Acids 15, 26-35, 2019 | 400 | 2019 |
| RNA containing modified nucleosides and methods of use thereof K Kariko, D Weissman US Patent 8,278,036, 2012 | 398 | 2012 |
| Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L BR Anderson, H Muramatsu, BK Jha, RH Silverman, D Weissman, ... Nucleic acids research 39 (21), 9329-9338, 2011 | 383 | 2011 |
Norbert PardiUniversity of PennsylvaniaVerified email at mail.med.upenn.edu
